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Genomics in medicine: From promise to practice
The culmination of the Human Genome Project, with 
the publication of two ‘reference’ genomes, intro-
duced the genomic era.[1,2]
Before this, human genetics concerned itself 
with techniques to analyse the chromosomes 
(cytogenetics) and to detect the genes causing Mendelian diseases 
such as cystic fibrosis or sickle cell anaemia (molecular genetics), 
and was largely the preserve of human geneticists. Genetic testing 
was accurate, but slow and costly. Chromosome analysis was 
limited by its low resolution (a DNA deletion of 5 million base 
pairs of DNA may be undetectable), and molecular genetics by 
the inability to sequence more than a few hundred DNA bases at 
a time.
The growth of genomics has been facilitated by the development 
of much more rapid and large-scale methods to analyse genetic 
information, including microarray and next-generation sequencing 
(NGS) technologies.
Available from the early 2000s, microarrays permitted testing 
for several million preselected items of genetic information in 
a single test. This allowed the development of approaches such 
as ‘molecular karyotyping’ and genome-wide association studies 
(GWASs).
The arrival of NGS in 2007 took this further, allowing sequencing 
of millions of segments of DNA in a single experiment. NGS may 
be used to test preselected genetic sequences, but may also be used 
for open-ended testing of the entire genome or large subsets thereof. 
This has been facilitated by great reductions in cost: since 2014 it 
has been possible to sequence a whole human genome for less than 
USD1 000.
Since each haploid genome comprises three billion base pairs of 
DNA, and any two human genomes are expected to have at least 
three million points of difference (genetic variants), the development 
of computational ‘bioinformatic’ methods has also been crucial. 
Computational algorithms using a range of public access databases 
provide the potential for clinically meaningful interpretation of 
genomic information. Comparison of a genomic test with the 
‘reference sequence’ and with databases of normal and pathogenic 
variants allows for classification of each piece of genomic information 
as ‘normal’, ‘pathogenic’ or a ‘variant of unknown significance’ 
(VOUS).
Cytogenetic disorders and microarray
Since microarray has been the forerunner to other genomic 
methods, it is instructive to track its role in cytogenetics. Molecular 
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karyotyping or array competitive genomic hybrid (array CGH) 
was introduced as a research technique for childhood intellectual 
disability over a decade ago. Compared with conventional 
karyotyping, array CGH can detect much smaller deletions or 
duplications of chromosome material (known as ‘copy number 
variants’). Evidence has accumulated that the cause of intellectual 
disability is detected in 15 - 20% of cases by array CGH compared 
with 3% by karyotyping. Over several years, array CGH transitioned 
into diagnostic practice as laboratories became more familiar with 
the methods involved, companies produced more user-friendly 
array platforms, and databases defined the normal and pathogenic 
genetic variants more clearly.
Array CGH is now rapidly supplanting chromosome analysis for 
investigation of intellectual disability, autism and multiple dysmorphic 
features of unknown cause,[3] and other indications.
Multifactorial disease and GWASs
Multifactorial diseases, resulting from the cumulative effect of 
multiple genetic and environmental predispositions, are a major 
contributor to the burden of disease in South Africa.[4] The GWAS 
research design allowed specific genetic loci to be linked to specific 
multifactorial diseases, and to date over 4 000 such loci have been 
detected.[5] Detection of a relevant locus permits further research to 
detect the specific genes and biochemical pathways involved, and 
potentially allows for new treatments to be developed.
Mendelian disorders and NGS
The arrival of NGS greatly accelerated inter alia the discovery of the 
genetic causes of Mendelian (single-gene) disorders. The genetic 
causes of over 3 600 single-gene disorders have been described 
to date.[5] Making a genetic diagnosis has many practical benefits. 
It clarifies the cause of the condition and ends the ‘diagnostic 
odyssey’. It allows for genetic counselling relating to options for 
preventing recurrence of the condition, including carrier testing, 
prenatal diagnosis, or possibly even preimplantation genetic 
diagnosis. In some instances the genetic test may alter treatment 
(e.g. a genetic diagnosis of Dravet’s syndrome indicates that certain 
antiepileptic drugs should be avoided). In a few instances it may 
allow for gene therapy that, although not a cure, significantly 
improves function. This is the case with RPE65 gene therapy for 
individuals with a particular cause of blindness, Leber’s congenital 
amaurosis.[6]
The laboratory method most often used to detect new or 
unidentified Mendelian disorders has been whole-exome sequencing 
(WES), since most mutations causing these disorders are within the 
1% of the genome that codes for proteins (i.e. the exome). WES is 
no longer just a research tool, and has gained an accepted diagnostic 
role for rare probably genetic disorders, with a 25% detection rate 
described by Yang et al.[7] In some instances the result has significantly 
changed clinical management – in one case prompting a curative 
bone marrow transplant for a child with intractable inflammatory 
bowel disease.[8]
Mendelian disorders that may be caused by mutations in any one 
of a number of known genes, such as familial cancers, visual loss, 
epilepsies or immunodeficiencies, can increasingly be diagnosed by 
means of sequencing a panel of genes known to cause that condition. 
Prior to the advent of NGS, such gene panels were impractical. 
Compared with WES, gene panels have the advantage of giving 
greater accuracy and less excess information.
Cell-free DNA and non-invasive 
prenatal testing (NIPT)
The detection of cell-free fetal DNA in the maternal plasma[9] allowed 
the development of NIPT. Early NIPT tested DNA sequences unique 
to the fetus, e.g. the presence of Y-chromosome DNA identified 
the fetus as male. More recently it has been possible to test for 
aneuploidies such as Down syndrome. The high sensitivity and 
specificity of NIPT for Down syndrome led to its rapid acceptance 
as a first-line screening method for women at high risk of having a 
child with Down syndrome.[10] Uptake of NIPT in the USA has been 
very rapid, with over 800 000 tests performed in 2014, to the extent 
that there have been concerns that testing is proceeding ahead of the 
clinical evidence.[11]
Cancer genomics
Cancer is a fundamentally genomic disorder, with tumorigenesis 
resulting from multiple mutations involving a variety of genes 
involved in control of the cell cycle and DNA repair.
Historically, tumour prognosis and treatment decisions have almost 
exclusively been determined by clinical staging and histological 
grading of the tumour. It has since become evident that tumours that 
look clinically and pathologically similar may have a very different 
molecular basis, which may be associated with different clinical 
outcomes. An early example was the finding that breast cancers 
over-expressing the HER-2 receptor are sensitive to treatment with a 
monoclonal antibody (Herceptin).
More recently gene-expression profiles for multiple genes, using 
mRNA extracted from tumour tissue, have become available to 
refine the prognosis of early-stage breast cancers, thereby improving 
decision-making regarding the need for chemotherapy.[12] For a range 
of cancers there is increasing evidence that the ‘molecular signature’ 
has great practical potential for determining diagnosis, prognosis and 
treatment.13]
Analogous to NIPT, it is possible to test for cell-free tumour DNA. 
This has a possible role as a biomarker for a variety of cancers, with 
potentially important implications for screening and monitoring.
Pharmacogenomics
Pharmacogenomics is the study of how genes affect a person’s 
response to particular drugs, and it aims to improve the efficacy, 
safety and dosing of medications. The efficacy of drugs as currently 
used is limited. Across a range of disorders, the proportion of patients 
who respond to treatment varies from 25% to 80%.[14] It is anticipated 
that improved molecular knowledge will improve drug targeting and 
increase the range of available drugs.
Accurate dosing is particularly important for drugs with a narrow 
therapeutic index, such as warfarin. Incorporating genetic information 
into decision-making on the warfarin dose was found to reduce the 
need for hospitalisations for haemorrhage by 28% in the 6 months after 
initiating therapy.[15] As a result, the Food and Drug Administration 
in the USA revised the label on warfarin to recommend the use of 
genotype information when prescribing warfarin and, based on this 
information, provision of genotype-specific dose ranges.[16]
In some cases, severe adverse events have been linked to 
specific genetic variants (e.g. HLA types). The finding that 
the HLA-B*5701 allele has good predictive value for abacavir 
hypersensitivity, and that this allele has a 5% prevalence in 
Caucasians, led to widespread implementation of genetic testing 
prior to initiation of therapy.[17]
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To date, the uptake of pharmacogenomic tests by clinicians has been 
relatively low internationally. Various reasons are cited, including 
uncertainty about the clinical utility of the test and the lack of simple 
clinical algorithms. A further complexity is that the prevalence of 
pharmacologically relevant variants is often not well characterised in 
local populations.[18]
Precision medicine
Precision medicine is set to become a paradigm for the medicine 
of the future. It builds upon several of the approaches described 
above, and involves more precise identification of a person’s illness 
at a genetic and biochemical level, whether it be hypertension 
or prostate cancer. More precise diagnosis will facilitate more 
precise treatment, using a currently available drug or perhaps a 
drug designed to take advantage of new biological knowledge. In 
addition, precision medicine should facilitate earlier diagnosis and 
prevention.
The recent announcement of a Precision Medicine Initiative by 
President Barack Obama[13] has given a significant boost to the field. 
It includes funding for a cohort of up to 1 million individuals who 
will be receiving extensive genomic testing and long-term clinical 
follow-up, in order to correlate genotypes, phenotypes and responses 
to treatment.
The implications of the precision medicine paradigm are far-
reaching in the long term. Everything, from the International 
Classification of Diseases to the use of electronic medical records to 
medical education to medical aid benefits, will change accordingly.[19]
Ethical and implementation challenges
Conventionally, diagnostic laboratory tests are assessed to ensure 
that they meet criteria for analytical validity (the assay should 
be accurate) and clinical validity (the test should be clinically 
meaningful).[20] Genomic testing challenges this paradigm because 
of the vast amount of information it produces. Genomic tests 
regularly detect VOUS, and it will take years to identify the 
clinical relevance of each variant. The need is for a flexible 
regulatory environment that stimulates rather than stifles 
research, while not condoning tests that are without clinical 
value. The Precision Medicine Initiative envisages an emphasis 
on developing collaborative public access databases to efficiently 
increase knowledge of the clinical implications of specific genetic 
variants.[13] A related challenge is how best to report the range 
of possible genetic variants detected, e.g. VOUS or ‘actionable’ 
incidental findings.[21]
As the ethical issues are solved and the evidence for clinical utility 
and cost-effectiveness becomes clearer, the use of genomic and 
precision medicine approaches will scale up. Given the complexities 
of implementation, it will initially require a multidisciplinary 
approach that includes both state-of-the-art molecular genomics 
and bioinformatic components, and insightful clinical and genetic 
counselling components.[22]
Conclusion
Genomics is a complex field that is taking an increasing role in many 
aspects of healthcare. Genomic medicine is expected to transition 
into the broader paradigm of precision medicine, with profound 
long-term implications for the practice of medicine and the training 
of future practitioners. 
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